Logo

Oxford Genome Sciences to Evaluate Bayer Diagnostics Breast Cancer Biomarkers

Mar 16, 2005

NEW YORK, March 16 (GenomeWeb News) -Oxford Genome Sciences will use its proteomics platform and its Oxford Genome Anatomy Project to evaluate biomarkers linked to breast cancer for Bayer HealthCare's diagnostics division, the companies said today.

 

Though financial terms of the agreement were not disclosed, Bayer said it "has committed program funding" to Oxford, and agreed to performance-related payments upon achieving certain milestones.

Bayer HealthCare hopes this research will help it discover and develop therapeutic and diagnostic products for breast cancer. 

According to Oxford, the OGAP proteomics database has more than 1 million peptide sequences from approximately 50 different tissues involved in almost 60 different diseases mapped onto 15,000 human genes.

Breaking News
The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.